<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04614025</url>
  </required_header>
  <id_info>
    <org_study_id>PLX-COV-03</org_study_id>
    <nct_id>NCT04614025</nct_id>
  </id_info>
  <brief_title>Open-label Multicenter Study to Evaluate the Efficacy of PLX-PAD for the Treatment of COVID-19</brief_title>
  <official_title>A Randomized, Controlled, Multicenter, Parallel-Group Phase IIa Study to Evaluate the Efficacy and Safety of Intramuscular Injections of PLX-PAD for the Treatment of Severe COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pluristem Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pluristem Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial will examine if a new treatment of Mesenchymal-like Adherent stromal&#xD;
      Cells (called PLX-PAD) can help patients intubated and mechanically ventilated due to&#xD;
      COVID-19 to recover more quickly with less complications.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 19, 2020</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Actual">August 4, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of ventilator-free days</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>28 and 60 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of mechanical ventilation</measure>
    <time_frame>28 and 60 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>COVID</condition>
  <condition>ARDS</condition>
  <arm_group>
    <arm_group_label>PLX-PAD Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PLX-PAD 300 million cells (20 million/mL) administered via 15 IM injections (1 mL each).&#xD;
Single administration in addition to best standard medical care.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Best standard medical care</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PLX-PAD</intervention_name>
    <description>PLX-PAD - allogeneic ex-vivo expanded placental mesenchymal-like adherent stromal cells</description>
    <arm_group_label>PLX-PAD Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Willing and able to provide written informed consent, or with a legal representative&#xD;
             who can provide informed consent.&#xD;
&#xD;
          -  Male or non-pregnant female adult 18-85 years of age at time of enrollment.&#xD;
&#xD;
          -  Laboratory-confirmed SARS-CoV-2 infection as determined by PCR, in any specimen up to&#xD;
             21 days prior to randomization.&#xD;
&#xD;
          -  Meets definition of ARDS according to Berlin criteria.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Body weight under 55 kg (121 lbs)&#xD;
&#xD;
          -  Serum creatinine level of over 1.5 mg/dL at time of randomization.&#xD;
&#xD;
          -  Total Bilirubin ≥2 mg/dL at time of randomization.&#xD;
&#xD;
          -  Known allergy to any of the following: dimethyl sulfoxide (DMSO), human serum albumin,&#xD;
             bovine serum albumin.&#xD;
&#xD;
          -  Stroke or acute myocardial infarction/unstable angina within 3 months prior to&#xD;
             randomization.&#xD;
&#xD;
          -  Chronic Obstructive Pulmonary disease GOLD stage above II.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Charite Campus Virchow</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Campus Benjamin Franklin - CBF Charité - Universitätsmedizin</name>
      <address>
        <city>Berlin</city>
        <zip>12203</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of hospital Bonn</name>
      <address>
        <city>Bonn</city>
        <zip>53127</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Cologne-Merheim</name>
      <address>
        <city>Köln</city>
        <zip>51109</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emek Medical Center</name>
      <address>
        <city>Afula</city>
        <zip>1834111</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bnai Zion Medical Center</name>
      <address>
        <city>Haifa</city>
        <zip>31048</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rambam Health Care Campus</name>
      <address>
        <city>Haifa</city>
        <zip>3109601</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galilee Medical Center</name>
      <address>
        <city>Nahariya</city>
        <zip>22100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baruch Padeh Medical Center, Poriya</name>
      <address>
        <city>Tiberias</city>
        <zip>15208</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Israel</country>
  </location_countries>
  <link>
    <url>http://www.pluristem.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>November 2, 2020</study_first_submitted>
  <study_first_submitted_qc>November 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 3, 2020</study_first_posted>
  <last_update_submitted>August 8, 2021</last_update_submitted>
  <last_update_submitted_qc>August 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

